On September 15, clinical-stage biopharmaceutical company Revelyx Bio, Inc. announced Dustin Sjuts as CEO and board member, and synchronized the positive results of the Phase II Australian clinical trial of its core asset YY003. The study reached the main end point. Among the subjects receiving the 40U dose, the 4-week comprehensive response rate reached 80.8%, compared with 0% compared to the placebo group. YY003 was generally well tolerated, and no serious treatment-related adverse events occurred.

On September 15, clinical-stage biopharmaceutical company Revelyx Bio, Inc. announced Dustin Sjuts as CEO and board member, and synchronized the positive results of the Phase II Australian clinical trial of its core asset YY003. The study reached the main end point. Among the subjects receiving the 40U dose, the 4-week comprehensive response rate reached 80.8%, compared with 0% compared to the placebo group. YY003 was generally well tolerated, and no serious treatment-related adverse events occurred.